| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Dec 10, 2025 | Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held | SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The ... |
| Oct 28, 2025 | Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC | SUZHOU, China, Oct. 28, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug... |
| Oct 27, 2025 | Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer | SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ... |
| Oct 24, 2025 | Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/αvβ6 Bispecfic ADC JSKN022 | SUZHOU, China, Oct. 24, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed at Sun Yat-sen University Cancer Center in the phase I clinical study (Study ID: JSKN022-101) ... |
| Oct 20, 2025 | Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer | SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibo... |
| Oct 18, 2025 | Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session | SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company an... |
| Sep 16, 2024 | Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 | SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European... |
| Jun 6, 2024 | Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products | SUZHOU, China, June 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and c... |
| Jun 3, 2024 | Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting | Results from the phase I part of JSKN003-102 was reported at this ASCO Annual Meeting.
JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonst... |
| May 22, 2024 | Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016 | SUZHOU, China, May 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (JSKN016-101) of JSKN016, a novel bispecific antibody-drug conjug... |
| May 6, 2024 | Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting | SUZHOU, China, May 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment ... |
| Apr 10, 2024 | Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR | The dose-escalation results of JSKN003 was reported at this AACR conference.
JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic soli... |
| Mar 29, 2024 | Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights | SUZHOU, China, March 29, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and highlighted recent progress and upcoming milestones.
Dr. Ting Xu, Chairman and CE... |
| Mar 22, 2024 | The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine | SUZHOU, China, March 22, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 plus chemotherapy as first-line treatment for metast... |
| Mar 14, 2024 | Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024 | SUZHOU, China, March 14, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase I clinical study conducted in Australia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the... |
| Jun 6, 2023 | Alphamab Oncology updated clinical research data for KN026 in Combination with KN046 in HER2-Positive Solid Tumors at the ASCO 2023 annual meeting | As of November 10, 2022, 26 patients with HER2-positive unresectable or metastatic solid tumors (other than breast cancer and gastric/gastroesophageal junction cancer) were enrolled, 92.3% of whom had received ≥2L prior systemic therapy. Th... |
| Apr 17, 2023 | Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023 | SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AA... |
| Mar 15, 2023 | Alphamab Oncology to Present the Preclinical Results of PD-L1/OX40 Bispecific Antibody KN052 at AACR 2023 | SUZHOU, China, March 15, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) is accepted as Late-Breaking Research in 114th Annual Meeting of the Ameri... |
| Dec 12, 2022 | Alphamab Oncology Presented Final Analysis of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at SABCS 2022 | As of August 21, 2022, the ORR from 25 efficacy evaluable TNBC patients was 44.0%, the DCR was 96.0%, and the CBR was 52.0%.
The median follow-up time was 27.93 months. The median PFS was 7.33 months. Among the PD-L1 ≥1% pts, the median PFS... |
| Dec 12, 2022 | Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel in first-line treatment of HER2-positive recurrent/metastatic breast cancer at SABCS 2022 | As of August 18, 2022，the confirmed ORR for 55 evaluable subjects was 76.4% and DoR was 24.0 months. The disease control rate was 100% in 55 evaluable subjects.
The median follow-up for PFS was 16.6 months. The median PFS was calculated as ... |
| Dec 12, 2022 | Alphamab Oncology Presented Clinical Data of KN026 Combined with Docetaxel as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer at SABCS 2022 | As of Sep 10, 2022, 20 patients completed the surgery and pathological evaluation, tpCR rate were 50%, bpCR rate were 55.0%, and ORR were 100%.
In terms of safety, the incidence Grade ≥3 TEAE were 53.3% (16/30)。The incidence of SAE was 6.7%... |
| Nov 22, 2022 | Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology | SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented a... |
| Aug 9, 2022 | First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer | SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase II clinical study (KN046-209) of PD-L1/CTLA-4 bispecific antibody KN046 plus Axitinib for the first ... |
| Jun 6, 2022 | Research Updates on KN046 Presented at 2022 ASCO | SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022... |
| Mar 9, 2022 | Alphamab Oncology to Present Clinical Data of KN026 Combined with KN046 in HER2-positive Solid Tumors at AACR 2022 | SUZHOU, China, March 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that data from phase II clinical study (KN026-203) of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) wil... |
| Jan 13, 2022 | Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046 | Interim analysis expected in the second quarter of 2022
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 ... |
| Dec 23, 2021 | Alphamab Oncology Announced First Patient Dosed in the U.S. in A Phase II Pivotal Clinical Study of KN046 | SUZHOU, China, Dec. 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced dosing of the first patient of its proprietary PD-L1/CTLA-4 bispecific antibody KN046 in the United States.
The patient received treatment in ENR... |
| Oct 29, 2021 | Alphamab Oncology Announces First Patient Dosed in the Pivotal Clinical Study of KN046 for the Treatment of PD-(L)1 Refractory Advanced NSCLC | SUZHOU, China, Oct. 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, a pivotal clinical study of PD-L1/CTLA-4 bispecific antibody KN046 in China (ENREACH-LUNG-02) recently completed the first drug administration.
... |
| Oct 18, 2021 | Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 | ENREACH-LUNG-01 is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study of KN046 combined with platinum-containing chemotherapy in patients with advanced unresectable or metastatic squamous NSCLC. Enrollment... |
| Aug 30, 2021 | Alphamab Oncology Reports 2021 Interim Results and Business Highlights | SUZHOU, China, Aug. 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), announced the company's interim results for the six months ended on June 30, 2021, and highlighted recent progress and upcoming milestones.
Dr. Ting Xu, C... |
| Aug 25, 2021 | 10 ways to reform the FDA's accelerated approval pathway: ICER and MSKCC offer options | Eli Lilly is staying busy during the summer months, wheeling and dealing its way to new deals. On Wednesday, the Big Pharma sealed its latest collaboration with a biotech focused on protein degradation.
Lilly is plunking down $35 million up... |
| Aug 25, 2021 | 10 ways to reform the FDA's accelerated approval pathway: ICER and MSKCC offer options | John Mascola, America’s soft-spoken, no-nonsense chief vaccinologist, spent 2020 on the fourth floor of the Vaccine Research Center in Bethesda, MD, primarily working on three projects. There’s a decent chance one of them has already been i... |
| Aug 25, 2021 | FibroGen, fresh off data manipulation scandal, touts win in cancer patients without revealing data | FibroGen’s lead drug has cleared another mid-stage study. Or at least the biotech claims it has.
FibroGen, a 28-year-old company whose stock collapsed this past year after it revealed data it had submitted to the FDA was mani... |
| Aug 25, 2021 | Covid-19 roundup: J&J offers new data to support boosters — but some experts are not impressed; Thailand university's robotic arm maximizes vaccine vials | Amidst all the booster shot talk with Pfizer and Moderna, J&J on Wednesday offered new data that may lead to its own single-shot booster.
New interim data from Phase I/IIa trials showed that J&J’s booster generated ... |
| Aug 25, 2021 | A Bristol Myers-backed biotech wants to treat heart disease with non-coding RNAs. It's one step closer to proof-of-concept | Is it possible to use strands of non-coding RNA, a burgeoning therapeutic area that researchers now believe plays an important part in how similar genes are expressed in different tissues, to treat heart disease? For Car... |
| Aug 25, 2021 | Chinese pharma groups partner in $150m licensing deal; Pfizer to join lawsuit on tariffs | Chinese pharma group Alphamab Oncology announced yesterday that its subsidiary signed a contract worth potentially as much as $150 million with JMT-Bio, a subsidiary of CSPC Pharmaceutical Group, to develop and comme... |
| Aug 25, 2021 | 10 ways to reform the FDA's accelerated approval pathway: ICER and MSKCC offer options | Little Cassava Sciences has complete faith in its experimental Alzheimer’s drug. Ever since pivoting away from a four-time reject analgesic (and from its former identity as Pain Therapeutics), the biotech has plowed steadily away at clinica... |
| Aug 24, 2021 | Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China | SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab" or "the Company"), a wholly-owned subsidiary of ... |
| Jun 30, 2021 | Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA | SUZHOU, China, June 30, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to envafolimab (KN035), a recombinant humanized PD-L1 singl... |
| Jun 7, 2021 | Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 | As of January 15, 2021, 9 patients were included in the efficacy analysis and 17 patients in the safety analysis. ORR was 55.6%, and DCR was 88.9%.
The updated results from this Phase II study will be presented at an upcoming medical meetin... |
| Jun 7, 2021 | Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 | KN046 combined with platinum doublet chemotherapy is tolerated and has shown promising clinical benefit as IL treatment for stage IV NSCLC.
OS rate at 12 months and 15 months were both 74.9%; Similar survival was observed in patients with P... |
| Jun 7, 2021 | Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 | SUZHOU, China, June 7, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced data from Phase 2 clinical study (KN046-204) of KN046(PD-L1/CTLA-4 bispecific antibody) plus paclitaxel/cisplatin for the first-line treatment of ... |
| May 24, 2021 | Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting | SUZHOU, China, May 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the study design of the ENVASARC pivotal trial in the U.S. of Envafolimab (KN035), a recombinant humanized PD-L1 single domain antibody independen... |
| Apr 12, 2021 | ALPHAMAB ONCOLOGY
Alphamab Oncology : VOLUNTARY ANNOUNCEMENT - PRELIMINARY SAFETY TOLERABILITY AND EFFICACY RESULTS OF KN046 IN COMBINATION WITH NAB-PACLITAXEL IN PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER RELEASED FOR E-POSTER PRESENTATION AT 2021 AACR ANNUAL MEETING | Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liabilit... |
| May 30, 2019 | China’s Alphamab Oncology raises $60m in Series B financing | Premium
Chinese biopharmaceutical company Alphamab Oncology has raised $60 million in a Series B financing round, led by Hudson Bay Capital Management LP, a US and UK-based asset management firm.
Continue reading this story with a subscript... |
| May 28, 2019 | Term Sheet — Tuesday May 28 | A TALE OF MANY MANY MERGERS
Hello again, Term Sheet readers! I hope y’all had a grill-filled Memorial Day. This is Lucinda, filling in for Polina who is on the West Coast until Friday. In the meantime, please send deals and thoughts to Luci... |
| May 28, 2019 | Alphamab Oncology Completes US$60M Series B Financing | Alphamab Oncology, a Suzhou, China-based biopharmaceutical company dedicated to global development of innovative biologics for cancer therapy, completed a US$60m Series B financing.
The round was led by Hudson Bay Capital Management LP with... |
| Nov 19, 2018 | PAG backs $100m Series A round for China’s Alphamab Oncology | Premium
Big-ticket investors including Hong Kong-based alternative investment firm PAG and China Venture Capital Fund (CVC) have invested in the $100-million Series A funding round for biopharma firm Alphamab Oncology, according to a compan... |
| Nov 19, 2018 | China’s Alphamab raises $100M in Series A financing from US, Asian investors | The company will devote the money to global clinical development of its pipeline, which includes four drugs currently in clinical development. These include KN035 (envafolimab), a subcutaneous monoclonal antibody that targets PD-L1 and is i... |
| Nov 19, 2018 | Term Sheet — Monday, November 19 | THE 2019 INVESTOR’S GUIDE
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
Perhaps, the most interesting and relevant topic to the Term Sheet audience is Fortune’s 2019 Investor Roundtable... |
| Nov 18, 2018 | Alphamab Oncology Completes Over $100M Series A Financing | Alphamab Oncology, a Suzhou, China-based clinical-stage biopharmaceutical company, raised more than $100m series A financing.
Backers included Advantech Capital, PAG, China Venture Capital Fund, OrbiMed, Heritage Provider Network and Jancho... |
| China’s Alphamab raises $100M in Series A financing from US, Asian investors | A Chinese startup has become the latest to raise a triple-digit sum in its first major venture capital fundraising from US as well as Asian backers.
Alphamab Oncology – based in Suzhou, Jiangsu province, near Shanghai – said Friday that it ... |